GxP inspections in 2026 are becoming more technology-aware, risk-focused and evidence-driven. Regulators are concentrating on how organisations manage data, quality systems and decision-making in real time. This blog outlines what health authorities are targeting now across GMP, GDP, medical devices and pharmacovigilance, and how companies can strengthen their readiness.
Read More: Why Your Pharmacovigilance System Master File Could Fail Your Next Inspection
1. Data Integrity: Still the Primary Focus, but Now More Technical
Data integrity remains the leading cause of major findings. Inspectors want to see end-to-end control across manufacturing, laboratory, logistics and safety systems.
Key areas authorities target
- Audit trail activation, retention and regular review
- Controls around data transfer between digital and manual processes
- Preservation of metadata and prevention of unofficial records
- Clearly documented, justified and traceable data corrections
- System access management and segregation of duties
Weaknesses here typically signal broader control issues, making this a top inspection theme every year.
2. AI, Automation and Algorithm Governance
As automation expands in manufacturing, logistics, QC and PV operations, regulators are evaluating whether AI-enabled tools are being managed with the same control as traditional GxP systems.
Inspectors are focusing on
- Risk classification of algorithms used in decision-making
- Documentation of datasets used for training or validation
- Human oversight and the ability to override automated outputs
- Traceability and version control when models are updated
- Supplier oversight for cloud-based AI systems
Any AI system that influences quality, batch release, distribution safety or case handling will attract detailed scrutiny.
3. Computerised System Assurance and Cybersecurity
GMP, GDP and PV environments now rely heavily on interconnected systems. Inspectors expect modern, risk-based validation and robust cybersecurity to protect data integrity and product safety.
Regulators check for
- Validation aligned to real business risks, not template-heavy documentation
- Cloud vendor assessment and contractual clarity
- Backup integrity, restore testing and secure system configurations
- Restricted and monitored system access
- Evidence of cybersecurity governance impacting GxP decisions
Poorly controlled digital systems are increasingly leading to major observations.
4. Remote and Hybrid Inspections: The Digital Day One Standard
Authorities frequently begin inspections remotely, requesting documents, logs and dashboards before visiting the site.
Key expectations
- Well-indexed, quickly retrievable digital records
- Clean, current versions of SOPs, batch records, QMS files and distribution logs
- Staff trained and prepared for remote interviews
- Screenshare-ready system walkthroughs
- Secure evidence-sharing platforms
Organisations unprepared for remote phases often start inspections on the back foot.
5. Pharmacovigilance: Accurate PSMFs and Evidence-Driven Signals
PV inspections are increasingly outcome-focused. Regulators expect systems that identify important risks early and demonstrate clear traceability from detection to action.
High-focus areas
- PSMF accuracy, alignment and regular updates
- Signal detection methods and justification for thresholds
- Traceability of decisions linked to safety actions
- Vendor oversight in multi-partner PV models
- Quality checks on ICSRs and aggregate reporting data
Superficial or outdated PSMFs continue to trigger major findings.
6. Supply Chain and Distribution: GDP Under the Spotlight
Global supply challenges have intensified GDP oversight. Inspectors want evidence that products are stored, transported and handled in full compliance with their authorised conditions.
Inspectors look for
- Robust qualification of transport partners
- Temperature monitoring, excursion handling and investigation quality
- Security of distribution routes and documentation
- Well-maintained premises and storage conditions
- Clear responsibilities defined in quality agreements
GDP weaknesses often reveal gaps in communication and operational control across the chain.
7. Medical Device Quality Systems: Post-Market Vigilance and Technical Documentation
Medical device regulators are sharpening oversight of lifecycle controls, especially post-market surveillance and risk management.
Areas of regulatory focus
- Adequacy of technical files and design documentation
- Change control and device lifecycle traceability
- Risk management linked back to real-world performance
- PMS evidence, trend analysis and incident handling
- Supplier controls for critical components and outsourced manufacture
Authorities expect proactive monitoring, not reactive reporting.
8. Quality Culture, Root Cause Analysis and CAPA Depth
Across GMP, GDP, devices and PV, regulators are evaluating whether companies learn from mistakes and strengthen systems, not just fix one-off issues.
Inspectors probe
- Quality of root-cause analysis and evidence used to justify it
- CAPA effectiveness and follow-up
- Trending of repeat issues
- Decision-making transparency
- Leadership involvement and oversight
Weak quality culture frequently shows up as repeated deviations or weak investigations.
9. Quick Wins for 2026 GxP Inspection Readiness
Companies can significantly improve readiness by ensuring the following:
- A mapped and controlled data lifecycle across all critical systems
- Up-to-date PSMF and PV traceability examples ready for inspection
- Risk-classified AI/automation tools documented and monitored
- Audit trails reviewed and ready for sampling
- GDP documentation clean, indexed and temperature-log evidence traceable
- Device technical documentation complete and current
- CAPA effectiveness records available and justified
- Remote inspection evidence pack prepared in advance
These actions create a strong first impression during early inspection stages.
How Quality and Vigilance Supports You in 2026
With increasing regulatory expectations, organisations need structured, reliable, and evidence-based compliance governance.
Quality and Vigilance LTD provides support across:
GMP Compliance – Ensuring robust manufacturing processes, data integrity, and CAPA management.
GDP Compliance – Supporting safe storage, transport, and full supply chain traceability.
Medical Devices – Assisting with technical documentation, risk management, and post-market surveillance.
Pharmacovigilance – PV system gap assessments, PSMF reviews, signal management, and inspection readiness.
Contact Q&V Ltd to enhance compliance, manage risks, and stay inspection-ready across manufacturing, distribution, medical devices, and pharmacovigilance.